| 1 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J/OL]. 中华移植杂志：电子版，2021, 15(6): 321-328.
|
| 2 |
Ling S, Jiang G, Que Q, et al. Liver transplantation in patients with liver failure: twenty years of experience from China[J]. Liver Int, 2022, 42(9)：2110-2116.
|
| 3 |
Nemes B, Gámán G, Polak WG, et al. Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(7)：841-859.
|
| 4 |
Nair A, Hashimoto K. Extended criteria donors in liver transplantation-from marginality to mainstream[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 386-388.
|
| 5 |
De Stefano N, Patrono D, Colli F, et al. Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors [J]. Cancers (Basel), 2024, 16(13): 2374.
|
| 6 |
Ho CM, Chen HL, Hu RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11：1758835919843463.
|
| 7 |
Sato K, Sekiguchi S, Kawagishi N, et al. Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy[J]. Clin Transplant, 2011, 25(1): 61-68.
|
| 8 |
Zhang Y, Jin W, Cai X. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis[J]. Ann Med, 2017, 49(5): 365-376.
|
| 9 |
Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage[J]. Liver Transpl, 2004, 10(6): 728-733.
|
| 10 |
Hashim M, Alsebaey A, Ragab A, et al. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: a single center study[J]. Ann Hepatol, 2020, 19(5): 541-545.
|
| 11 |
Eberhardt TE, Kim DH, Nethersole S, et al. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients[J]. Clin Transplant, 2024, 38(6): e15332.
|
| 12 |
Swarup R, Allenspach LL, Nemeh HW, et al. Timing of basiliximab induction and development of acute rejection in lung transplant patients[J]. J Heart Lung Transplant, 2011, 30(11): 1228-1235.
|
| 13 |
Crins ND, Röver C, Goralczyk AD, et al. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies[J]. Pediatr Transplant, 2014, 18(8): 839-850.
|
| 14 |
Martín-Mateos RM, Graus J, Albillos A, et al. Initial immunosuppression with or without basiliximab: a comparative study[J]. Transplant Proc, 2012, 44(9): 2570-2572.
|
| 15 |
Vondran FW, Timrott K, Tross J, et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation[J]. Transpl Int, 2010, 23(5): 514-523.
|
| 16 |
Cillo U, De Carlis L, Del Gaudio M, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group [J]. Hepatol Int, 2020, 14(6): 930-943.
|
| 17 |
Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients [J]. Liver Transpl, 2011, 17(Suppl 3): S1-S9.
|
| 18 |
Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation[J]. Clin Exp Immunol, 2005, 139(1): 2-10.
|
| 19 |
Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation[J]. World J Hepatol, 2015, 7(10): 1355-1368.
|
| 20 |
Penninga L, Wettergren A, Wilson CH, et al. Antibody induction versus corticosteroid induction for liver transplant recipients[J]. Cochrane Database Syst Rev, 2014, 2014(5): CD010252.
|
| 21 |
Kirk AD. Induction immunosuppression[J]. Transplantation, 2006, 82(5): 593-602.
|
| 22 |
Choudhary NS, Saigal S, Shukla R, et al. Current status of immunosuppression in liver transplantation[J]. J Clin Exp Hepatol, 2013, 3(2): 150-158.
|
| 23 |
Lladó L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study[J]. J Hepatol, 2006, 44(4): 710-716.
|
| 24 |
Trezeguet Renatti G, Riva N, Minetto J, et al. Feasibility of steroid-free tacrolimus-basiliximab immunosuppression in pediatric liver transplantation and predictors for steroid requirement [J]. Liver Transpl, 2024, 30(1): 61-71.
|
| 25 |
Dong C, Song Z, Sun C, et al. Basiliximab induction and postoperative steroid-free immunosuppression with tacrolimus in pediatric liver transplantation: a randomized clinical trial [J]. Transplantation, 2024, 108(8): 1769-1775.
|
| 26 |
Zhang GQ, Zhang CS, Sun N, et al. Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(2): 139-146.
|
| 27 |
Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial[J]. Liver Transpl, 2002, 8(2): 132-142.
|
| 28 |
Schmeding M, Sauer IM, Kiessling A, et al. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial[J]. Ann Transplant, 2007, 12(3): 15-21.
|
| 29 |
Lupo L, Panzera P, Tandoi F, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial[J]. Transplantation, 2008, 86(7): 925-931.
|
| 30 |
Kathirvel M, Mallick S, Sethi P, et al. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)[J]. HPB (Oxford), 2021, 23(5): 666-674.
|
| 31 |
Ganschow R, Broering DC, Stuerenburg I, et al. First experience with basiliximab in pediatric liver graft recipients [J]. Pediatric transplantation, 2001, 5(5): 353-358.
|
| 32 |
Ganschow R, Grabhorn E, Schulz A, et al. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients [J]. Pediatr Transplant, 2005, 9(6): 741-745.
|
| 33 |
Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression [J]. Am J Transplant, 2006, 6(8): 1913-1921.
|
| 34 |
中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植，2019, 10(3): 213-226.
|
| 35 |
Cederborg A, Norén Å，Barten T, et al. Renal function after liver transplantation: real-world experience with basiliximab induction and delayed reduced-dose tacrolimus [J]. Dig Liver Dis, 2022, 54(8): 1076-1083.
|
| 36 |
Zhang L, Liu P, Zhuang L, et al. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma [J]. Mol Biomed, 2024, 5(1): 9.
|
| 37 |
Saliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial [J]. Am J Transplant, 2017, 17(7): 1843-1852.
|
| 38 |
Newland DM, Royston MJ, McDonald DR, et al. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients [J]. Pediatr Transplant, 2019, 23(8): e13573.
|
| 39 |
Herrmann BN, Moore CA, Johnson HJ, et al. Evaluation of single versus two-dose basiliximab induction therapy in live-donor liver transplant [J]. Clin Transplant, 2024, 38(10): e70006.
|
| 40 |
Durand F, Francoz C, Asrani SK, et al. Acute kidney injury after liver transplantation [J]. Transplantation, 2018, 102(10): 1636-1649.
|
| 41 |
Thongprayoon C, Kaewput W, Thamcharoen N, et al. Incidence and impact of acute kidney injury after liver transplantation: a meta-analysis [J]. J Clin Med, 2019, 8(3) ：372.
|
| 42 |
Zhou J, Zhang X, Lyu L, et al. Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis [J]. BMC Nephrol, 2021, 22(1): 149.
|
| 43 |
Toniutto P, Germani G, Ferrarese A, et al. An essential guide for managing post-liver transplant patients: what primary care physicians should know [J]. Am J Med, 2022, 135(2): 157-166.
|
| 44 |
Panackel C, Mathew JF, Fawas NM, et al. Immunosuppressive drugs in liver transplant: an insight [J]. J Clin Exp Hepatol, 2022, 12(6): 1557-1571.
|
| 45 |
Levitsky J, O′Leary JG, Asrani S, et al. Protecting the kidney in liver transplant recipients: practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice [J]. Am J Transplant, 2016, 16(9): 2532-2544.
|
| 46 |
Duvoux C, Pageaux GP. Immunosuppression in liver transplant recipients with renal impairment [J]. J Hepatol, 2011, 54(5): 1041-1054.
|
| 47 |
Lin CC, Chuang FR, Lee CH, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation [J]. Liver Transpl, 2005, 11(10): 1258-1264.
|
| 48 |
Schnitzbauer AA, Sothmann J, Baier L, et al. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07) [J]. Transplantation, 2015, 99(12): 2565-2575.
|
| 49 |
Boyd A, Brown A, Patel J, et al. Basiliximab with delayed tacrolimus improves short-term renal outcomes post-liver transplantation-a real-world experience[J]. Transplant Proc, 2021, 53(5): 1541-1547.
|
| 50 |
Xiao M, Xu X, Zhu H, et al. Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study [J]. Int J Clin Pract Suppl, 2015, (183): 35-42.
|
| 51 |
Wei Q, Xu X, Wang C, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma [J]. Gut Liver, 2016, 10(4): 604-610.
|
| 52 |
Marino IR, Doria C, Scott VL, et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients [J]. Transplantation, 2004, 78(6): 886-891.
|
| 53 |
Gruttadauria S, Vasta F, Mandalà L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation [J]. Transplant Proc, 2005, 37(6): 2611-2613.
|
| 54 |
Xue M, Lv C, Chen X, et al. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: a retrospective cohort study [J]. J Diabetes, 2016, 8(4): 579-587.
|
| 55 |
Best LM, Leung J, Freeman SC, et al. Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis [J]. Cochrane Database Syst Rev, 2020, 1(1): CD013203.
|
| 56 |
Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2022 annual data report: liver [J]. Am J Transplant, 2024, 24(2): S176-S265.
|
| 57 |
Mugaanyi J, Tong J, Lu C, et al. Risk factors for acute rejection in liver transplantation and its impact on the outcomes of recipients [J]. Transpl Immunol, 2023, 76: 101767.
|
| 58 |
Maurice JB, Nwaogu A, Gouda M, et al. Acute antibody-mediated rejection in liver transplantation: impact and applicability of the Banff working group on liver allograft pathology 2016 criteria [J]. Hum Pathol, 2022, 127: 67-77.
|
| 59 |
张晋平，朱志军，孙丽莹，等. 抗胸腺细胞球蛋白治疗肝移植术后耐激素急性排斥反应1例报告并文献复习[J]. 精准医学杂志，2022, 37(5): 396-399，403.
|
| 60 |
Bijleveld CG, Klompmaker IJ, van den Berg AP, et al. Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation [J]. Transpl Int, 1996, 9(6): 570-575.
|
| 61 |
卢新军，陈颖华，马毅，等. 原位肝移植术后耐激素性急性排斥反应的临床诊治策略[J]. 中华肝脏病杂志，2016, 24(4)：297-301.
|
| 62 |
Wu L, Tam N, Deng R, et al. Steroid-resistant acute rejection after cadaveric liver transplantation: experience from one single center [J]. Clin Res Hepatol Gastroenterol, 2014, 38(5): 592-597.
|
| 63 |
Benjamin MM, Dasher KJ, Trotter JF. A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients [J]. Transplantation, 2014, 97(4): 470-473.
|
| 64 |
Lee JG, Lee J, Lee JJ, et al. Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation [J]. Medicine (Baltimore), 2016, 95(23): e3711.
|
| 65 |
Semash K, Dzhanbekov T, Nasirov M, et al. Bortezomib as a potential treatment for recurrent autoimmune hepatitis following pediatric liver transplantation [J]. Pediatr Transplant, 2025, 29(4): e70082.
|
| 66 |
Chariat MN, Erren M, Chariat M, et al. Basiliximab in the therapy of acute rejection after organ transplantation [J]. Transplant Proc, 2001, 33(3): 2380.
|
| 67 |
Aw MM, Taylor RM, Verma A, et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1 [J]. Transplantation, 2003, 75(6): 796-799.
|
| 68 |
Shigeta T, Sakamoto S, Uchida H, et al. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure [J]. Pediatr Transplant, 2014, 18(8): 860-867.
|
| 69 |
Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab [J]. Transplantation, 2003, 76(3): 459-463.
|
| 70 |
Han JW, Joo DJ, Kim JH, et al. Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction [J]. Am J Transplant, 2020, 20(8): 2058-2069.
|
| 71 |
Leonard PA, Woodside KJ, Gugliuzza KK, et al. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody [J]. Transplantation, 2002, 74(12): 1697-1700.
|
| 72 |
Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basiliximab in renal transplantation [J]. Drug Saf, 2004, 27(2)：91-106.
|
| 73 |
Héquet D, Pascual M, Lartey S, et al. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies [J]. Vaccine, 2016, 34(31): 3576-3583.
|
| 74 |
中华预防医学会过敏病预防与控制专业委员会预防食物药物过敏学组. 药物过敏诊断和预防方案中国专家共识[J]. 中华预防医学杂志，2022, 56(6): 682-706.
|
| 75 |
国家药品监督管理局. 国家药监局关于修订注射用巴利昔单抗说明书的公告(2020年第27号)[EB/OL]. (2020-03-09) [2025-09-01].
URL
|
| 76 |
Wang W, Yin H, Li XB, et al. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin [J]. Chin Med J (Engl), 2012, 125(6)：1135-1140.
|
| 77 |
Clinckart F, Bulpa P, Jamart J, et al. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation [J]. Transplant Proc, 2009, 41(2): 607-609.
|
| 78 |
Lee JY, Kim YH, Yi NJ, et al. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation [J]. Clin Mol Hepatol, 2014, 20(2): 192-203.
|
| 79 |
Durkin C, Schaubel DE, Xu Y, et al. Induction immunosuppression does not worsen tumor recurrence after liver transplantation for hepatocellular carcinoma [J]. Transplantation, 2023, 107(7): 1524-1534.
|